论文部分内容阅读
目的 :探讨急性白血病 (AL )患者中端粒酶活性与突变型 p5 3蛋白的表达规律。方法 :采用聚合酶链反应—酶联免疫吸附法 (PCR- EL ISA )对端粒酶活性进行半定量测定 ,用流式细胞仪检测突变型 p5 3蛋白表达。结果 :AL患者端粒酶活性显著高于对照组 (P<0 .0 0 1) ;端粒酶活性在 AL的不同病期有统计学差异 ,其中初治组、复发组均显著高于完全缓解 (CR)组 (P<0 .0 1) ;在治疗敏感组与不敏感组间无统计学差异 (P>0 .0 5 )。 AL患者中突变型 p5 3蛋白阳性率为 19.4% (7/36 ) ,在 AL的不同病期 p5 3阳性率无统计学差别 ;在初治敏感组与不敏感组之间亦无统计学差别 (P均 >0 .0 5 )。端粒酶活性与突变型 p5 3蛋白的表达无关。结论 :端粒酶活性与 AL的病期和发展密切相关 ;突变型 p5 3蛋白在 AL中表达较低 ,对临床预后的判断价值较小 ;端粒酶的激活与 p5 3蛋白表达无相关性。
Objective: To investigate the expression of telomerase activity and mutant p53 protein in patients with acute leukemia (AL). METHODS: Semiquantitative telomerase activity was detected by polymerase chain reaction-enzyme-linked immunosorbent assay (PCR-EL ISA). The expression of mutant p53 protein was detected by flow cytometry. Results: The telomerase activity in AL patients was significantly higher than that in the control group (P < 0.01). The telomerase activity was statistically different in different stages of AL. The initial treatment group and relapse group were significantly higher than those in the complete treatment group. There was no statistical difference between the treatment-sensitive group and the insensitive group (P>0.05). The positive rate of mutant p53 protein in AL patients was 19.4% (7/36). There was no significant difference in the positive rate of p53 in different disease stages of AL patients. There was no statistical difference between the initial treatment sensitive group and insensitive group. (P all> 0. 0 5). Telomerase activity was not associated with mutant p53 protein expression. Conclusion: The activity of telomerase is closely related to the stage and development of AL. The expression of mutant p53 protein is low in AL and has little value in judging the clinical prognosis. There is no correlation between the activation of telomerase and the expression of p53 protein. .